(Total Views: 317)
Posted On: 01/06/2022 11:21:51 AM
Post# of 24

$RFL News Article - Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase 1/2 Clinical Trial of CPI-613 (Devimistat) in Patients with Relapsed Clear Cell Sarcoma https://marketwirenews.com/news-releases/rafa...23190.html


My Twitter: WhyteStocks